Matthew J. Wieduwilt

University of San Diego — United States

Medicine · Health Sciences

32h-index6.4kcitations142works10.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(58), Acute Lymphoblastic Leukemia research(57), Chronic Myeloid Leukemia Treatments(34), Chronic Lymphocytic Leukemia Research(20), Hematopoietic Stem Cell Transplantation(19)

Publications141 total

Lack of efficacy of levocarnitine for the treatment of pegylated asparaginase-related hepatotoxicity during induction or salvage chemotherapy in adults with acute lymphoblastic leukemia: A comparative, retrospective, University of California hematologic malignancies consortium (UCHMC) study
Blood·2025
Efficacy and safety of loncastuximab tesirine and rituximab (Lonca-R) followed by dose-adjusted rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine and prednisone (DA-R-EPOCH) in previously untreated high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary results from a University of California Malignancy Consortium (UCHMC) Phase II trial, UCDCC#303.
Blood·2025Open Access
Somatic mutations and clinical outcomes in primary central nervous system lymphoma among hispanic and non-hispanic patients: A study from the University of California hematologic malignancies consortium (UCHMC)
Blood·2025Open Access
Daunorubicin and cytarabine liposomal (CPX-351) plus glasdegib for newly diagnosed secondary Acute Myeloid Leukemia: Results of University of California hematologic malignancies consortium trial 1913
Blood·2025
Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab
Blood·2025
Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survival
Blood·2025Open Access
Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial
Blood·2025Open Access
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results
Journal of Clinical Oncology·2025· 2 cited
A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)
Leukemia Research·2025· 1 cited
Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis
Blood Neoplasia·2025· 1 citedOpen Access
CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial
Leukemia & lymphoma/Leukemia and lymphoma·2024· 1 cited
Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with <i>BCR::ABL1</i> Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
Blood·2024
Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
Blood·2024· 2 citedOpen Access
The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia
Blood·2024· 1 cited
Development of Inotuzumab Ozogamicin and Blinatumomab for Frontline Treatment of Older Patients with Ph-Negative B-Cell Acute Lymphoblastic Leukemia
Clinical Lymphoma Myeloma & Leukemia·2024
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
New England Journal of Medicine·2024· 172 citedOpen Access
Need for consensus on primary end points and efficacy definitions in trials for adult acute lymphoblastic leukemia
Blood Advances·2024· 2 citedOpen Access
Precision Oncology in Hematological Malignancies: Takeaways from the 2023 Precision Oncology Summit
International Journal of Cancer Care and Delivery·2024Open Access
Long-Term Follow up for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
Blood·2023· 12 cited
Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial
Blood·2023· 14 cited
page 1 of 8Next →

Frequent Co-authors

Geoffrey L. Uy(22), Richard M. Stone(16), Anjali S. Advani(13), Mark R. Litzow(13), Jeffrey E. Lancet(11), Tara L. Lin(11), Martin S. Tallman(11), Dale L. Bixby(10), Stephen A. Strickland(9), Gary J. Schiller(9), Harry P. Erba(9), Ryan J. Mattison(9), Jonathan E. Kolitz(8), Farhad Ravandi(8), Jörge E. Cortes(7), Amir T. Fathi(7), Marcos de Lima(7), Ibrahim Aldoss(7), Michaela Liedtke(7), Ehab Atallah(7)